The PGA TOUR and Lilly ICOS Announce Multi-Year Partnership; New Western Open Sponsor Introduces Broadcast Vignette Program and Co-Sponsored Scoreboards

Business Wire, Nov 5, 2003

Sports Editors/Health/Medical Writers

HOUSTON--(BUSINESS WIRE)--Nov. 5, 2003

Lilly ICOS LLC, a joint venture between ICOS Corporation (Nasdaq:ICOS) and Eli Lilly and Company (NYSE:LLY), today has entered into a four-year sponsorship agreement with the PGA TOUR. Lilly ICOS becomes an official partner of both the PGA TOUR and Champions Tour beginning in 2004. The joint announcement was made today at Champions Golf Club in Houston, site of this week's THE TOUR Championship presented by Coca-Cola(R).

To support the partnership, the PGA TOUR and Lilly ICOS are developing a series of golf-themed vignettes featuring top players from both Tours. The vignettes will focus primarily on the emotional connection to the game with themes such as relaxation, preparation and confidence. The motivational vignettes will air during PGA TOUR telecasts throughout 2004 and will be featured on PGATOUR.COM. The agreement also includes an on-site component, whereby Lilly ICOS will join MasterCard(R) as a sponsor of the electronic scoreboards at PGA TOUR and Champions Tour events. As such, it will receive a dedicated ad panel on each scoreboard. Lilly ICOS will also have the right to use the PGA TOUR logo in advertising.

Lilly ICOS, which was introduced as the new title sponsor of the Western Open on July 1, 2003, is also developing an integrated program to further support its connection to golf and leverage its association with the PGA TOUR. These plans will be announced at a later date.

"We are extremely pleased that such an outstanding company has expanded its involvement with the TOUR through a marketing relationship, just four months after agreeing to become the title sponsor of the Western Open," said Tom Wade, the PGA TOUR's Chief Marketing Officer. "We have been working together for well over a year to develop an integrated marketing platform which we're confident will provide value to both Lilly ICOS and the PGA TOUR."

"Lilly ICOS is delighted to join the PGA TOUR family as an official partner," said Paul Clark, Chairman and Chief Executive Officer of ICOS and a member of the Lilly ICOS board. "Those who watch and play golf are an important audience for us. A partnership with the PGA TOUR allows us to connect with millions of golf fans, many of whom enjoy golf because it is both relaxing and invigorating."

About the PGA TOUR

The PGA TOUR is a tax-exempt membership organization of professional golfers. Its primary purpose is to provide significant competitive earnings opportunities for past, current and future members of the PGA TOUR, Champions Tour and Nationwide Tour; to protect the integrity of the game; and to help grow the reach of the game in the U.S. and around the world.

Approximately 120 events are being contested on the three Tours in 2003, for more than $290 million in prize money. In addition to providing competitive opportunities for its membership, TOUR events also generate significant sums of money for charity. TOUR events have raised more than $750 million for charity since 1938, the first year such records were kept. The PGA TOUR's Web site address is www.pgatour.com.

About Lilly ICOS

Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli Lilly and Company, is developing Cialis(R) (tadalafil) for the treatment of erectile dysfunction. Lilly ICOS received an approvable letter for Cialis from the U.S. Food and Drug Administration in April 2002 and anticipates approval of Cialis late in 2003. Cialis is approved for sale in more than 45 countries, including countries in Europe and in Australia, Brazil, Mexico, Russia, and Saudi Arabia.

Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

ICOS Corporation is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products expected to have significant commercial potential. ICOS applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis and other inflammatory diseases. ICOS' strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing ICOS' opportunities to market breakthrough products.

Forward-Looking Statement

Certain of the matters discussed herein with respect to clinical studies and commercial plans for ICOS and Lilly's products may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about the industry, management beliefs and certain assumptions made by management. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties, including economic, competitive, governmental, technological and other factors discussed in the two companies' respective filings with the Securities and Exchange Commission, which may affect the business and prospects of the two companies. More specifically, there can be no assurance that this product will receive regulatory approvals as expected or achieve commercial success or that competing products will not pre-empt any market opportunity that might exist for the product. The companies undertake no duty to update forward-looking statements.